Granted Patent
B2
US 12,629,696 · App. 18/542,486 · Granted May 19, 2026
Dielectric materials
Inventors:
Juan Pablo Hinestrosa Salazar (San Diego, CA); Rajaram Krishnan (San Diego, CA); Scott Conradson (San Diego, CA); Tyler Lee Harris (San Diego, CA); Robert Paul Turner (San Diego, CA); George Maroor Thomas (San Diego, CA)
Assignee:
Xzom, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure describes methods, devices and systems comprising materials comprising dielectrics. In various aspects, electrodes layered or imbedded with these dielectrics provide enhanced properties for a wide range of applications, such as the enhanced separation of analytes, such as biological molecules or particles (nucleic acids, viruses) with an electrokinetic field.
Claims (46)
1 . A method of diagnosing a disease or condition in a patient comprising:
(a) applying a sample to a device to capture a plurality of analytes in the sample, wherein the device comprises an electrode configured to generate an electrokinetic force; and a layer in contact with at least a portion of the electrode, wherein the layer comprises a dielectric material of about 5 angstroms to about 25 angstroms in thickness, wherein the device increases the total yield of analyte captured as compared to a device that lacks a layer or has a layer that is more than 25 angstroms in thickness;
(b) detecting the plurality of analytes captured; and
(c) comparing an amount of each of the plurality of analytes in the sample to a respective known standard to diagnose the disease or condition in the patient.
2 . The method of claim 1 , wherein the plurality of analytes comprises nanoscale particles.
3 . The method of claim 1 , wherein the plurality of analytes comprises proteins, lipids, antibodies, nucleic acids, tumor cells, extracellular vesicles, exosomes, nucleosomes, nanosomes, or any combination thereof.
4 . The method of claim 1 , wherein detecting the amount of each of the plurality of analytes comprises determining a relative concentration of the analyte in the sample.
5 . The method of claim 1 , wherein the electrophoretic force is an AC or DC electrophoretic force.
6 . The method of claim 1 , further comprising producing at least one of an AC dielectrophoretic or an AC electrokinetic field region.
7 . The method of claim 1 , further comprising isolating the plurality of analytes in at least one of an AC dielectrophoretic and/or an AC electrokinetic field region.
8 . The method of claim 1 , wherein the electrophoretic force comprises a dielectrophoretic field, a DC electrophoretic force, an electrothermal field, an electroosmotic field, or a combination thereof.
9 . The method of claim 1 , wherein the dielectric material comprises a metalloid oxide, metalloid nitride, metalloid carbide, metalloid silicide, or combination thereof.
10 . The method of claim 9 , wherein the metalloid is selected from the group consisting of boron, silicon, germanium, arsenic, antimony, tellurium, and combinations thereof.
11 . The method of claim 1 , wherein the dielectric material comprises a metal.
12 . The method of claim 11 , wherein the metal is selected from the group consisting of platinum, ruthenium, rhodium, iridium, manganese, magnesium, tungsten, zirconium, chromium, gold, iron, aluminum, tantalum, gallium, copper, silver, brass, zinc, tin, nickel, palladium, titanium, cobalt, indium, bismuth, lead, lanthanum, hafnium, yttrium, calcium, strontium, barium, cadmium, mercury, thallium, antimony, germanium, and combinations thereof.
13 . The method of claim 1 , wherein the dielectric material comprises an organic or inorganic polymer.
14 . The method of claim 1 , wherein the dielectric material comprises a ceramic.
15 . The method of claim 1 , wherein the dielectric material has a dielectric constant of about 2 to about 10.
16 . The method of claim 1 , wherein the layer comprises a material selected from the group consisting of silicon, silicon oxide, silicon nitride, silicon carbide, titanium oxide, germanium, polytetrafluoroethylene, neoprene, polyvinylidene fluoride, silicon dioxide, titanium dioxide, fluorosilicate glass, polyimide, fluorinated polyimide, methylsilsesquioxane, polyarylene ether, polyethylene, polystyrene, calcium carbonate, and combinations thereof.
17 . The method of claim 1 , wherein the electrode comprises a conductive material.
18 . The method of claim 17 , wherein the mole ratio of dielectric to conductive material is about 0.01:2 to about 99:1.
19 . The method of claim 17 , wherein the mole ratio of dielectric to conductive material is about 0.3:2.
20 . The method of claim 17 , wherein the conductive material comprises at least one of the group consisting of platinum, gold, aluminum, tantalum, gallium arsenide, copper, silver, brass, zinc, tin, nickel, silicon, palladium, titanium, graphite, carbon, and combinations thereof.
21 . A method of monitoring a disease or condition in a patient comprising:
(a) applying a sample to a device to capture a plurality of analytes in the sample, wherein the device comprises an electrode configured to generate an electrokinetic force; and a layer in contact with at least a portion of the electrode, wherein the layer comprises a dielectric material of about 5 angstroms to about 25 angstroms in thickness, wherein the device increases the total yield of analyte captured as compared to a device that lacks a layer or has a layer that is more than 25 angstroms in thickness;
(b) detecting the plurality of analytes captured; and
(c) measuring an amount of each of the plurality of analytes in the sample to monitor the disease or condition in the patient.
22 . The method of claim 21 , wherein the plurality of analytes comprises nanoscale particles.
23 . The method of claim 21 , wherein the plurality of analytes comprises proteins, lipids, antibodies, nucleic acids, tumor cells, extracellular vesicles, exosomes, nucleosomes, nanosomes, or any combination thereof.
24 . The method of claim 21 , wherein measuring the amount of each of the plurality of analytes comprises determining a relative concentration of the analyte in the sample.
25 . The method of claim 21 , wherein the electrophoretic force is an AC or DC electrophoretic force.
26 . The method of claim 21 , further comprising producing at least one of an AC dielectrophoretic or an AC electrokinetic field region.
27 . The method of claim 21 , further comprising isolating the plurality of analytes in at least one of an AC dielectrophoretic or an AC electrokinetic field region.
28 . The method of claim 21 , wherein the electrophoretic force comprises a dielectrophoretic field, a DC electrophoretic force, an electrothermal field, an electroosmotic field, or a combination thereof.
29 . The method of claim 21 , wherein the dielectric material comprises a metalloid oxide, metalloid nitride, metalloid carbide, metalloid silicide, or combination thereof.
30 . The method of claim 29 , wherein the metalloid is selected from the group consisting of boron, silicon, germanium, arsenic, antimony, tellurium, and combinations thereof.
31 . The method of claim 21 , wherein the dielectric material comprises a metal.
32 . The method of claim 31 , wherein the metal is selected from the group consisting of platinum, ruthenium, rhodium, iridium, manganese, magnesium, tungsten, zirconium, chromium, gold, iron, aluminum, tantalum, gallium, copper, silver, brass, zinc, tin, nickel, palladium, titanium, cobalt, indium, bismuth, lead, lanthanum, hafnium, yttrium, calcium, strontium, barium, cadmium, mercury, thallium, antimony, germanium, and combinations thereof.
33 . The method of claim 21 , wherein the dielectric material comprises an organic or inorganic polymer.
34 . The method of claim 21 , wherein the dielectric material comprises a ceramic.
35 . The method of claim 21 , wherein the dielectric material has a dielectric constant of about 2 to about 10.
36 . The method of claim 21 , wherein the layer comprises a material selected from the group consisting of silicon, silicon oxide, silicon nitride, silicon carbide, titanium oxide, germanium, polytetrafluoroethylene, neoprene, polyvinylidene fluoride, silicon dioxide, titanium dioxide, fluorosilicate glass, polyimide, fluorinated polyimide, methylsilsesquioxane, polyarylene ether, polyethylene, polystyrene, calcium carbonate, and combinations thereof.
37 . The method of claim 21 , wherein the electrode comprises a conductive material.
38 . The method of claim 37 , wherein the mole ratio of dielectric to conductive material is about 0.01:2 to about 99:1.
39 . The method of claim 37 , wherein the mole ratio of dielectric to conductive material is about 0.3:2.
40 . The method of claim 37 , wherein the conductive material comprises at least one of the group consisting of platinum, gold, aluminum, tantalum, gallium arsenide, copper, silver, brass, zinc, tin, nickel, silicon, palladium, titanium, graphite, carbon, and combinations thereof.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 2, 2025
From: JACOBS FAMILY TRUST
To: XZOM, INC.
Reel/Frame 071014/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 28, 2025
From: BIOLOGICAL LIQUIDATION, LLC
To: JACOBS FAMILY TRUST
Reel/Frame 070965/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 24, 2025
From: BIOLOGICAL DYNAMICS, INC.
To: BIOLOGICAL LIQUIDATION, LLC
Reel/Frame 070940/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 17, 2025
From: HINESTROSA SALAZAR, JUAN PABLO; KRISHNAN, RAJARAM; CONRADSON, SCOTT; HARRIS, TYLER LEE; TURNER, ROBERT PAUL; THOMAS, GEORGE MAROOR
To: BIOLOGICAL DYNAMICS, INC.
Reel/Frame 070876/0134 →
Continuity (3)
Continuation
17045146
Provisional Application
62651659
· Apr 2, 2018
References Cited (400)
US 5632957A
· Heller et al.
· 1997
[cited by applicant]
US 5958791A
· Roberts et al.
· 1999
[cited by applicant]
US 6149789A
· Benecke et al.
· 2000
[cited by applicant]
US 6203683B1
· Austin et al.
· 2001
[cited by applicant]
US 6280590B1
· Cheng et al.
· 2001
[cited by applicant]
US 6289590B1
· McDonald
· 2001
[cited by applicant]
US 6294063B1
· Becker et al.
· 2001
[cited by applicant]
US 6335167B1
· Pinkel et al.
· 2002
[cited by applicant]
US 6352838B1
· Krulevitch et al.
· 2002
[cited by applicant]
US 6403367B1
· Cheng et al.
· 2002
[cited by applicant]
US 6557575B1
· Gerhardt et al.
· 2003
[cited by applicant]
US 6749736B1
· Fuhr et al.
· 2004
[cited by applicant]
US 6824664B1
· Austin et al.
· 2004
[cited by applicant]
US 6887362B2
· Huang et al.
· 2005
[cited by applicant]
US 7081189B2
· Squires et al.
· 2006
[cited by applicant]
US 7105081B2
· Gascoyne et al.
· 2006
[cited by applicant]
US 7447922B1
· Asbury et al.
· 2008
[cited by applicant]
US 7611908B2
· Miller et al.
· 2009
[cited by applicant]
US 7615381B2
· Masters et al.
· 2009
[cited by applicant]
US 7648844B2
· Srivastava et al.
· 2010
[cited by applicant]
US 7709262B2
· Cantor et al.
· 2010
[cited by applicant]
US 8372657B2
· Reboud et al.
· 2013
[cited by applicant]
US 8383061B2
· Prakash et al.
· 2013
[cited by applicant]
US 8425750B2
· Sugioka
· 2013
[cited by applicant]
US 8603791B2
· Krishnan et al.
· 2013
[cited by applicant]
US 8815554B2
· Krishnan et al.
· 2014
[cited by applicant]
US 8815555B2
· Krishnan et al.
· 2014
[cited by applicant]
US 8871481B2
· Krishnan et al.
· 2014
[cited by applicant]
US 8877470B2
· Krishnan et al.
· 2014
[cited by applicant]
US 8932447B2
· Heller et al.
· 2015
[cited by applicant]
US 8932815B2
· Krishnan et al.
· 2015
[cited by applicant]
US 8969059B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9005941B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9034578B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9034579B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9169521B1
· Rajagopal et al.
· 2015
[cited by applicant]
US 9206416B2
· Krishnan et al.
· 2015
[cited by applicant]
US 9387489B2
· Charlot et al.
· 2016
[cited by applicant]
US 9499812B2
· Krishnan et al.
· 2016
[cited by applicant]
US 9682385B2
· Charlot et al.
· 2017
[cited by applicant]
US 9827565B2
· Krishnan et al.
· 2017
[cited by applicant]
US 9918702B2
· Tariyal et al.
· 2018
[cited by applicant]
US 20020036142A1
· Gascoyne et al.
· 2002
[cited by applicant]
US 20040011650A1
· Zenhausern et al.
· 2004
[cited by applicant]
US 20040011651A1
· Becker et al.
· 2004
[cited by applicant]
US 20040052689A1
· Yao
· 2004
[cited by applicant]
US 20040086872A1
· Childers et al.
· 2004
[cited by applicant]
US 20060096367A1
· Meyer et al.
· 2006
[cited by applicant]
US 20060102482A1
· Auerswald et al.
· 2006
[cited by applicant]
US 20060194008A1
· Schwartz et al.
· 2006
[cited by applicant]
US 20060228749A1
· Wang et al.
· 2006
[cited by applicant]
US 20070080062A1
· Harnett et al.
· 2007
[cited by applicant]
US 20070095669A1
· Lau et al.
· 2007
[cited by applicant]
US 20070131554A1
· Yu et al.
· 2007
[cited by applicant]
US 20070141605A1
· Vann et al.
· 2007
[cited by applicant]
US 20070152206A1
· Cho et al.
· 2007
[cited by applicant]
US 20070240495A1
· Hirahara
· 2007
[cited by applicant]
US 20070289341A1
· Hollenhorst et al.
· 2007
[cited by applicant]
US 20090061450A1
· Hunter
· 2009
[cited by applicant]
US 20090123516A1
· Agrawal et al.
· 2009
[cited by applicant]
US 20090314644A1
· Golan et al.
· 2009
[cited by applicant]
US 20090325813A1
· Wang et al.
· 2009
[cited by applicant]
US 20100155246A1
· Schnelle et al.
· 2010
[cited by applicant]
US 20100211407A1
· Duke et al.
· 2010
[cited by applicant]
US 20110009724A1
· Hill et al.
· 2011
[cited by applicant]
US 20110020785A1
· Lowery, Jr. et al.
· 2011
[cited by applicant]
US 20110100820A1
· Bachmann et al.
· 2011
[cited by applicant]
US 20110108422A1
· Heller et al.
· 2011
[cited by applicant]
US 20110192726A1
· Chen et al.
· 2011
[cited by applicant]
US 20130052748A1
· Campbell et al.
· 2013
[cited by applicant]
US 20130274148A1
· Kain et al.
· 2013
[cited by applicant]
US 20140054172A1
· Jonsson et al.
· 2014
[cited by applicant]
US 20140170679A1
· Aitchison et al.
· 2014
[cited by applicant]
US 20140367260A1
· Dickerson et al.
· 2014
[cited by applicant]
US 20150136604A1
· Nielsen et al.
· 2015
[cited by applicant]
US 20150219618A1
· Krishnan et al.
· 2015
[cited by applicant]
US 20160232562A1
· Esayian et al.
· 2016
[cited by applicant]
US 20160327549A1
· Charlot et al.
· 2016
[cited by applicant]
US 20170370836A1
· Gerion et al.
· 2017
[cited by applicant]
US 20180274014A1
· Krishnan et al.
· 2018
[cited by applicant]
US 20180345284A1
· Charlot et al.
· 2018
[cited by applicant]
US 20210020275A1
· Krishnan et al.
· 2021
[cited by applicant]
US 20210214798A1
· Krishnan et al.
· 2021
[cited by applicant]
US 20220228193A1
· Jones et al.
· 2022
[cited by applicant]
US 20240069035A1
· Krishnan et al.
· 2024
[cited by applicant]
CA 2870160A1
· 2013
[cited by applicant]
CN 1337580A
· 2002
[cited by applicant]
CN 1348100A
· 2002
[cited by applicant]
CN 101208593A
· 2008
[cited by applicant]
CN 100417936C
· 2008
[cited by applicant]
CN 102037351A
· 2011
[cited by applicant]
CN 102320559A
· 2012
[cited by applicant]
CN 104583420A
· 2015
[cited by applicant]
CN 106459966A
· 2017
[cited by applicant]
CN 107107562A
· 2017
[cited by applicant]
EP 1775589A1
· 2007
[cited by applicant]
GB 2516666A
· 2015
[cited by applicant]
JP H0663360A
· 1994
[cited by applicant]
JP H11514087A
· 1999
[cited by applicant]
JP 2001500252A
· 2001
[cited by applicant]
JP 2002502047A
· 2002
[cited by applicant]
JP 2004532968A
· 2004
[cited by applicant]
JP 2005501251A
· 2005
[cited by applicant]
JP 2006135191A
· 2006
[cited by applicant]
JP 2008298575A
· 2008
[cited by applicant]
JP 2011516867A
· 2011
[cited by applicant]
JP 2011522219A
· 2011
[cited by applicant]
JP 2013536679A
· 2013
[cited by applicant]
JP 2013232627A
· 2013
[cited by applicant]
JP 2017512483A
· 2017
[cited by applicant]
JP 2018535088A
· 2018
[cited by applicant]
TW 201726540A
· 2017
[cited by applicant]
WO WO9804355A1
· 1998
[cited by applicant]
WO WO9938612A1
· 1999
[cited by applicant]
WO WO0196025A2
· 2001
[cited by applicant]
WO WO2005012872A2
· 2005
[cited by applicant]
WO WO2005031300A2
· 2005
[cited by applicant]
WO WO2005121767A1
· 2005
[cited by applicant]
WO WO2006018981A1
· 2006
[cited by applicant]
WO WO2006120656A1
· 2006
[cited by applicant]
WO WO2007106552A2
· 2007
[cited by applicant]
WO WO2007107910A1
· 2007
[cited by applicant]
WO WO2009146143A2
· 2009
[cited by applicant]
WO WO2012028746A1
· 2012
[cited by applicant]
WO WO2013060762A1
· 2013
[cited by applicant]
WO WO2013112425A1
· 2013
[cited by applicant]
WO WO2013158686A1
· 2013
[cited by applicant]
WO WO2014011740A1
· 2014
[cited by applicant]
WO WO2014015187A1
· 2014
[cited by applicant]
WO WO2014028222A1
· 2014
[cited by applicant]
WO WO2014207731A1
· 2014
[cited by applicant]
WO WO2015038797A1
· 2015
[cited by applicant]
WO WO2015097858A1
· 2015
[cited by applicant]
WO WO2015148808A1
· 2015
[cited by applicant]
WO WO2015157217A1
· 2015
[cited by applicant]
WO WO2015196141A1
· 2015
[cited by applicant]
WO WO2016025698A1
· 2016
[cited by applicant]
WO WO2016179308A1
· 2016
[cited by applicant]
WO WO2017075295A1
· 2017
[cited by applicant]
WO WO2017125475A1
· 2017
[cited by applicant]
WO WO2017165852A1
· 2017
[cited by applicant]
WO WO2017181030A2
· 2017
[cited by applicant]
WO WO2018112265A1
· 2018
[cited by applicant]
WO WO2018208820A1
· 2018
[cited by applicant]
WO WO2019126388A1
· 2019
[cited by applicant]
WO WO2019126391A1
· 2019
[cited by applicant]
WO WO2019195196A1
· 2019
[cited by applicant]
WO WO2019200323A1
· 2019
[cited by applicant]
WO WO2022011313A1
· 2022
[cited by applicant]
WO WO2022155223A1
· 2022
[cited by applicant]
Hagiwara, Kei, et al. High co-expression of large tenascin C splice variants in stromal tissue and annexin A2 in cancer cell membranes is associated with poor prognosis in pancreatic cancer. Annals of Surgical Oncology …
[cited by applicant]
Lewis, Jean M., et al. Integrated analysis of exosomal protein biomarkers on alternating current electrokinetic chips enables rapid detection of pancreatic cancer in patient blood. ACS nano 12.4: 3311-3320. (2018).
[cited by applicant]
Angerer et al. Demonstration of tissue-specific gene expression by in situ hybridization. Methods Enzymol 152:649-660 (1987).
[cited by applicant]
Asbury, et al., Trapping of DNA by Dielectrophoresis. Electrophoresis 23:2658-2666 (2002).
[cited by applicant]
Asbury, et al., Trapping of DNA in Nonuniform Oscillating Electric Fields. Biophysical Journal 74:1024-1030 (1998).
[cited by applicant]
Becker, et al., Separation of Human Breast Cancer Cells From Blood by Differential Dielectric Affinity. Proceedings of the National Academy of Sciences 92:860-864 (1995).
[cited by applicant]
Becker, et al., The Removal of human Leukemia Cells from Blood using Interdigitated Microelectrodes. Journal Physics D: Applied Physics 27:2659-2662 (1994).
[cited by applicant]
Berg, et al., Cellphone-Based Hand-Held Microplate Reader for Point-of-Care Testing of Enzyme-Linked Immunosorbent Assays. ACS NANO 9(8):7857-7866 (2015).
[cited by applicant]
Bettegowda, et al., Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science translational medicine 6(224):1-25 (2014).
[cited by applicant]
Board, et al., DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer. Biomark Insights 2:307-319 (2007).
[cited by applicant]
Board, et al., Isolation and Extraction of Circulating tumor DNA from Patients with Small Cell Lung Cancer. Annals of the New York Academy of Sciences 1137:98-107 (2008).
[cited by applicant]
Cairns, Detection of Promoter Hypermethylation of Tumor Suppressor Genes in Urine from kidney Cancer Patients. Annals of the New York Academy of Sciences 1022:40-43 (2004).
[cited by applicant]
Casciano, et al., Circulating Tumor Nucleic Acids: Perspective in Breast Cancer. Breast Care 5:75-80 (2010).
[cited by applicant]
Catarino, et al., Quantification of Free Circulating Tumor DNA as a Diagnostic marker for Breast Cancer. DNA and cell biology 27(8):415-421 (2008).
[cited by applicant]
Cetin et al. Microfluidic bio-particle manipulation for biotechnology. Biochemical Engineering Journal 92:63-82 (2014).
[cited by applicant]
Chan, et al., Circulating EBV DNA as a Tumor Marker for Nasopharyngeal Carcinoma. Seminars in cancer biology 12(6):489-496 (2002).
[cited by applicant]
Chan, et al., Nasopharyngeal carcinoma. Annals of Oncology 13:1007-1015 (2002).
[cited by applicant]
Chan, et al., Persistent Aberrations in Circulating DNA Integrity after Radiotherapy are Associated with Poor Prognosis in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research 14(13):4141-4145 (2008).
[cited by applicant]
Chan, et al., Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma. Clinical Chemistry 54(9):1528-1536 (2008).
[cited by applicant]
Chan, et al., Radiological, Pathological and DNA Remission in Recurrent Metastatic Nasopharyngeal Carcinoma. BMC Cancer 6(259):1-5 (2006).
[cited by applicant]
Cheng, et al., Isolation of Cultured Cervical Carcinoma Cells Mixed with Peripheral Blood Cells on a Bioelectronic Chip. Analytical Chemistry 70(11):2321-2326 (1998).
[cited by applicant]
Cheng, et al., Preparation and Hybridization Analysis of DNA/RNA from
[cited by applicant]
Cheng, et al., Quantification of Circulating cell-free DNA in the Plasma of cancer Patients during radiation therapy. Cancer Science 100(2):303-309 (2009).
[cited by applicant]
Choi et al. Microfluidic-based biosensors toward point-of-care detection of nucleic acids and proteins. Microfluidics And Nanofluidics 10(2):231-247 (2010).
[cited by applicant]
Chuang, et al., Detectable BRAF Mutation in Serum DNA Samples from Patients with Papillary Thyroid Carcinomas. Head Neck 32(2):229-234 (2010).
[cited by applicant]
Chun, et al., Circulating tumour-associated Plasma DNA Represents an independent and informative predictor of prostate cancer. BJU International 98(3):544-548 (2006).
[cited by applicant]
Cohen, et al., Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359(6378): 926-930 (2018).
[cited by applicant]
Combaret, et al., Circulating MYCN DNA as a Tumor-specific Marker in Neuroblastoma Patients. Cancer Research 62:3646-3648 (2002).
[cited by applicant]
Cortese, et al., Epigenetic markers of prostate cancer in plasma circulating DNA. Human Molecular Genetics 21:3619-3631 (2012).
[cited by applicant]
Da Silva, et al., Circulating cell-free DNA in serum as a biomarker of colorectal cancer. Journal of Clinical Pathology 66(9):775-778 (2013).
[cited by applicant]
Daniotti, et al., Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. International journal of cancer 120:2439-2444 (2007).
[cited by applicant]
Dawson, et al., Analysis of circulating tumor DNA to Monitor Metastatic Breast cancer. The New England journal of medicine 368:1199-1209 (2013).
[cited by applicant]
De Maio, et al., Circulating and Stool Nucleic Acid Analysis for Colorectal Cancer Diagnosis. World Journal of Gastroenterology 20(4):957-967 (2014).
[cited by applicant]
Delgado, Characterization of Cell-free Circulating DNA in Plasma in Patients with Prostate Cancer. Tumour biologyl 34(2):983-986 (2013).
[cited by applicant]
Deligezer, et al., Effect of Adjuvant Chemotherapy on Integrity of free Serum DNA in Patients with Breast Cancer. Annals of the New York Academy of Sciences. 1137:175-179 (2008).
[cited by applicant]
Devos, et al., Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal Cancer. Clinical Chemistry 55(7):1337-1346 (2009).
[cited by applicant]
Dobrzycka, et al., Circulating free DNA and p53 Antibodies in Plasma of Patients with Ovarian Epithelial Cancers. Annals of Oncology 22(5):1133-1140 (2011).
[cited by applicant]
Dobrzycka, et al., Circulating free DNA, p53 Antibody and Mutations of KRAS Gene in Endometrial Cancer. 127(3):612-621 (2010).
[cited by applicant]
Dvorak, Vascular Permeability Factor/Vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of clinical oncology 20(21):4368-4380 (2002).
[cited by applicant]
El Tarhouny, et al., Comparison of Serum VEGF and its Soluble Receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine 44(1):65-69 (2008).
[cited by applicant]
Ellinger, et al., Cell-free Circulating DNA: Diagnostic Value in Patients with Testicular Germ Cell Cancer. The Journal of urology. 181(1):363-371 (2009).
[cited by applicant]
Ellinger, et al., CpG Island Hypermethylation of Cell-free Circulating Serum DNA in Patients with Testicular Cancer. The Journal of urology 182(1):324-329 (2009).
[cited by applicant]
Ellinger, et al., Noncancerous PTGS2 DNA fragments of Apoptotic Origin in Sera of Prostate Cancer Patients Qualify as Diagnostic and Prognostic Indicators. International Journal of Cancer 122(1):138-143 (2008).
[cited by applicant]
Elshimali, et al., The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients. International journal of molecular sciences 14(9):18925-18958 (2013).
[cited by applicant]
Fuhr, et al., Cell manipulation and cultivation under a.c. electric field influence in highly conductive culture media. Biochimica et Biophysica Acta 1201:353-360 (1994).
[cited by applicant]
Gahan, et al., Circulating Nucleic Acids in plasma and serum: diagnosis and prognosis in cancer. EPMA Journal 1(3):503-512 (2010).
[cited by applicant]
Ganepola, et al., Use of Blood-Based Biomarkers for Early Diagnosis and Surveillance of Colorectal Cancer. World Journal of Gastrointestinal Oncology 6(4):83-97 (2014).
[cited by applicant]
Gao, et al., Increased Integrity of Circulating Cell-free DNA in Plasma of Patients with Acute Leukemia. Clinical chemistry and laboratory medicine 48(11):1651-1656 (2010).
[cited by applicant]
Gautschi, et al., Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. Journal of clinical oncology 22(20):4157-4164 (2004).
[cited by applicant]
Goessl, et al., DNA Alterations in Body Fluids as Molecular Tumor Markers for Urological Malignancies. European Urology 41(6):668-676 (2002).
[cited by applicant]
Gornik, et al., Free Serum DNA is an early Predictor of Severity of Acute Pancreatitis. Clinical biochemistry 42(1-2):38-43 (2009).
[cited by applicant]
Green, et al., Ac Electrokinetics: a Survey of Sub-Micrometre Particle Dynamics.Journal Physics D: Applied Physics 33:632-641 (2000).
[cited by applicant]
Guan, et al., Analysis of Circulating DNA level in the Plasma of Cervical Cancer Patients. Journal of Southern Medical University. 28(9):1663-1667 (2008).
[cited by applicant]
Haeberle et al. Centrifugal extraction of plasma from whole blood on a rotating disk. Lab Chip 6(6):776-781 (2006).
[cited by applicant]
Hashad, et al., Free circulating Tumor DNA as a Diagnostic Marker for Breast Cancer. Journal of clinical laboratory analysis 26(6):467-472 (2012).
[cited by applicant]
Higgins, et al., Variant Ciz1 is a Circulating biomarker for early-stage lung cancer. PNAS USA 109(45):E3128-3135 (Nov. 6, 2012).
[cited by applicant]
Higuchi, Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress. Biochem Pharacol. 66:1527-1535(2003).
[cited by applicant]
Higuchi, et al., Appearance of 1-2 Mbp giant DNA fragments as an early common response leading to cell death induced by various substances that cause oxidative stress. Free Radical Biology & Medicine 23:90-99 (1997).
[cited by applicant]
Hinestrosa, et al., Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform. Front Bioeng Biotechnol. 8(581157):1-13 (2…
[cited by applicant]
Hoffmann, et al., Methylated DAPK and APC promoter DNA Detection in Peripheral Blood is significantly associated with apparent residual tumor and outcome. Journal of Cancer Research and Clinical Oncology 135(89):1231-12…
[cited by applicant]
Hoffmann, et al., Universal protocol for grafting PCR primers onto various lab-on-a-chip substrates for solid-phase PCR. RSC Advances 2:3885-3889 (2012).
[cited by applicant]
Hohaus, et al., Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Annals of Oncology 20(8):1408-1413 (2009).
[cited by applicant]
Holdhoff, et al., Blood-based biomarkers for malignant gliomas.Journal of Neuro-Oncology 113:345-352 (2013).
[cited by applicant]
Holzel, et al., Trapping Single Molecules by Dielectrophoresis. Physical review letters 95:128102 (2005).
[cited by applicant]
Hoshino, et al., Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell 182(4):1044-1061.E18 (2020).
[cited by applicant]
Hoshino, et al., Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329-335 (2015).
[cited by applicant]
Hosny, et al., Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. Cancer Letter 264(2):201-208 (2008).
[cited by applicant]
Huang, et al., Dielectrophoretic Cell Separation and Gene Expression Profiling on Microelectronic Chip Arrays. Analytical chemistry 74:3362-3371 (2002).
[cited by applicant]
Huang, et al., Electric Manipulation of Bioparticles and Macromolecules on Microfabricated Electrodes. Analytical Chemistry (73):1549-1559 (2001).
[cited by applicant]
Huang, et al., Functionalization of Surfaces by Water-Accelerated Atom-Transfer Radical Polymerization of Hydroxyethyl Methacrylate and Subsequent Derivatization. Macromolecules 35:1175-1179 (2002).
[cited by applicant]
Hughes, Chapter 16: Nanoparticle Manipulation by Electrostatic Forces. Handbook of Nanoscience, Engineering and Technology 2nd Ed., WA Goddard III, DW Brenner, S. Lyshenski & G. lafrate (eds.) 1-32 (2007).
[cited by applicant]
Hughes, et al., Dielectrophoretic Characterization and Separation of Antibody-Coated Submicrometer Latex Spheres. Analytical chemistry 71:3441-3445 (1999).
[cited by applicant]
Hughes, et al., Dielectrophoretic Manipulation and Characterization of Herpes Simplex Virus-1 Capsids.European biophysics journal 30:268-272 (2001).
[cited by applicant]
Hughes, Strategies for Dielectrophoretic Separation in Laboratory-on-a-chip Systems. Electrophoresis 23:2569-2582 (2002).
[cited by applicant]
Iida, et al., Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma. Oncology Reports 20(4):761-765 (2008).
[cited by applicant]
Iizuka, et al., Elevated Levels of Circulating Cell-free DNA in the Blood of Patients with Hepatitis C Virus-associated Hepatocellular Carcinoma. Anticancer Research 26(6C):4713-4720 (2006).
[cited by applicant]
Jiang, et al., Dynamic monitoring of plasma circulating DNA in patients with acute myeloid leukemia and its clinical significance. Journal of experimental hematology 20(1):53-56 (2012).
[cited by applicant]
Jiang, et al., Increased plasma DNA integrity index in head and neck cancer patients. International Journal of Cancer 119(11):2673-2676 (2006).
[cited by applicant]
Jin, et al., Circulating DNA-Important Biomarker of Cancer. Journal of Molecular Biomarkers & Diagnosis S2:1-7 (2012).
[cited by applicant]
Juppner, Functional properties of the PTH/PTHrP receptor. Bone. 17(2):Supplement 39S-42S (1995).
[cited by applicant]
Kakimoto, et al., Microsatellite analysis of serum DNA in patients with oral squamous cell carcinoma. Oncology Reports 20(5):1195-1200 (2008).
[cited by applicant]
Kjaergaard, et al., The use of the soluble adhesion molecules sE-selectin, sICAM-1, sVCAM-1, sPECAM-1 and their ligands CD11a and CD49d as diagnostic and prognostic biomarkers in septic and critically ill non-septic ICU…
[cited by applicant]
Kolesnikova, et al., Circulating DNA in the blood of gastric cancer patients.Annals of the New York Academy of Sciences 1137:226-231 (2008).
[cited by applicant]
Krishnan et al. Alternating current electrokinetic separation and detection of DNA nanoparticles in high-conductance solutions. Electrophoresis 29(9):1765-1774 (2008).
[cited by applicant]
Krishnan et al. An AC electrokinetic method for enhanced detection of DNA nanoparticles. J. Biophotonics 2(4):253-261 (2009).
[cited by applicant]
Krishnan et al. Interaction of nanoparticles at the DEP microelectrode interface under high conductance conditions. Electrochem. Comm. 11(8):1661-1666 (2009).
[cited by applicant]
Kuhlmann, et al., LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer 12:3525 (2012).
[cited by applicant]
Lavon, et al., Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncology 12(2):173-180 (2010).
[cited by applicant]
Lee, et al., A micro cell lysis device. Sensors and Actuators A: Physical. 73(1-2):74-79 (1999).
[cited by applicant]
Lee, et al., Methylation of TMEFF2 Gene in Tissue and Serum DNA from Patients with Non-Small Cell Lung Cancer. Molecules and Cells 34(2):171-176 (2012).
[cited by applicant]
Lennartsson, et al., Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiological reviews 92(4):1619-1649 (2012).
[cited by applicant]
Li et al. Alternating current electrokinetics enhanced in situ capacitive immunoassay. Electrophoresis 36(3):471-474 (2015).
[cited by applicant]
Lida, et al., Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma.Oncology reports 20(4):761-5 (2008).
[cited by applicant]
Liggett, et al., Differential Methylation of Cell-Free Circulating DNA Among Patients With Pancreatic Cancer Versus Chronic Pancreatitis. Cancer 116(7):1674-1680 (2010).
[cited by applicant]
Liggett, et al., Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. International Journal of Cancer 128(2):492-499 (2011).
[cited by applicant]
Liu, et al., Sensitive and Specific Multi-Cancer Detection and Localization Using Methylation Signatures in Cell-Free DNA. Annals of Oncology 31(6):745-759 (2020).
[cited by applicant]
Lo Nigro, et al., Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma. Journal of Investigative Dermatology 133(5):1278-1285 (2013).
[cited by applicant]
Lofton-Day, et al., DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening. Clinical Chemistry 54(2):414-423 (2008).
[cited by applicant]
Lu, et al., Abstract: AC electrokinetic isolation of cell free high molecular weight DNA (CF-HMW DNA) from serum. American Association for Cancer Research Publication 72(8):1704 (2012).
[cited by applicant]
Ma, et al., Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients.Chinese journal of pathology 34(12):785-787 (2005).
[cited by applicant]
Ma, et al., Methylated DNA and microRNA in Body Fluids as Biomarkers for Cancer Detection. International Journal of Molecular Sciences 14(5):10307-10331 (2013).
[cited by applicant]
Majchrzak, et al., Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. Journal of applied genetics 54:335-344 (2013).
[cited by applicant]
Melnikov et al. Methylation Profile of circulating plasma DNA in patients with pancreatic cancer. Journal of surgical oncology 99(2):119-122 (2009).
[cited by applicant]
Menachery, et al., Controlling cell destruction using dielectrophoretic forces. IEE proceedings Nanobiotechnology 152(4):145-149 (2005).
[cited by applicant]
Mirza, et al., Clinical Significance of Promoter Hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients. Annals of Surgical Oncology 19(9):3107-3115 (2012).
[cited by applicant]
Misale, et al., Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in Colorectal Cancer. Nature 486(7404):532-536 (2012).
[cited by applicant]
Misawa, et al., RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. British Journal of Cancer 100:399-404 (2009).
[cited by applicant]
Moasser, The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469-6487 (2007).
[cited by applicant]
Moreira, et al., Cell-free DNA as a Noninvasive Acute Rejection marker in renal Transplantation. Clinical Chemistry 55(11):1958-66 (2009).
[cited by applicant]
Morgan, et al., Separation of Sub Micron Bioparticles by Dielectrophoresis Biophysical Journal.77:516-525 (1999).
[cited by applicant]
Mouliere, et al., Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Translational Oncology 6(3):319-328 (2013).
[cited by applicant]
Mouliere, et al., High fragmentation characterizes tumour-derived circulating DNA. PLoS One 6(9):e23418 (2011).
[cited by applicant]
Muller, et al., DNA Methylation in Serum of Breast Cancer Patients: An Independent Prognostic Marker. Cancer Research 63(22):7641-7645 (2003).
[cited by applicant]
Muller, et al., Identification of Loss of Heterozygosity on Circulating Free DNA in Peripheral Blood of Prostate Cancer Patients: Potential and Technical Improvements. Clinical Chemistry 54(4):688-696 (2008).
[cited by applicant]
Nakagawa, et al., Fabrication of amino Silane-Coated Microchip for DNA extraction from Whole Blood. Journal of Biotechnology 116(2):105-111 (2005).
[cited by applicant]
Nakamoto, et al., Detection of Microsatellite Alterations in Plasma DNA of Malignant Mucosal Melanoma Using Whole Genome Amplification. The Bulletin of Tokyo Dental College 49(2):77-87 (2008).
[cited by applicant]
Nakamura, et al., Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA. Journal of Thoracic Oncology 7(9):1369-1381 (2012).
[cited by applicant]
Nakayama, et al., A Highly Sensitive Method for the Detection of p16 Methylation in the Serum of Colorectal Cancer Patients. Anticancer Research 27(3B):1459-1464 (2007).
[cited by applicant]
Niland, et al., Neuropilins in the Context of Tumor Vasculature. Int J Mol Sci. 20(3):639: 1-44 (2019).
[cited by applicant]
Ohwaki, Characterization Of Native Oxide On Aluminum By Infrared Spectroscopy. Journal of Japan Institute of Light Metals. vol. No. 54, Issue No. 1 (2004): pp. 31-36.
[cited by applicant]
Page, et al., Detection of HER2 amplification in circulating free DNA in patients with breast cancer. British Journal of Cancer 104:1342-1348 (2011).
[cited by applicant]
Pang et al. Microsatellite alterations of circulating DNA in the plasma of patients with hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 86(24):1662-1665 (Jun. 27, 2006) (Abstract).
[cited by applicant]
Papadopoulou et al., Cell-free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer, Ann. NY, Acad. Sci. 1075:235-243 (2006).
[cited by applicant]
Parker et al. mRNA: detection by In Situ and northern hybridization. Methods Mol Biol 106:247-283 (1999).
[cited by applicant]
Persat, et al., Purification of Nucleic Acids from Whole Blood Using Isotachophoresis. Analytical Chemistry 81.22: 9507-9511 (2009), supporting materials.
[cited by applicant]
Pethig, et al., Dielectrophoresis: Using Inhomogenous AC Electrical Fields to Separate and Manipulate Cells. CRC Critical Reviews in Biotechnology 16(4):331-348 (1996).
[cited by applicant]
Ponomaryova, et al., Potentialities of Aberrantly Methylated Circulating Dna for Diagnostics and Post-treatment Follow-up of Lung Cancer Patients. Lung Cancer 81(3):397-403 (2013).
[cited by applicant]
Quesada-Gonzalez, et al., Mobile Phone-based Biosensing: an Emerging “Diagnostic and Communication” Technology. Biosensors And Bioelectronics 92:549-562 (2016).
[cited by applicant]
Ramos, et al., Ac Electrokinetics: a Review of Forces in Microelectrode Structures. Journal of Physics D: Applied Physics 31:2338-2353 (1998).
[cited by applicant]
Ren, et al., Circulating DNA Level is Negatively Associated With the Long-term Survival of Hepatocellular Carcinoma Patients. World Journal of Gastroenterology 12(24):3911-3914 (2006).
[cited by applicant]
Ross, et al., Binding Affinity of Surface Functionalized Gold Nanoparticles to Hydroxyapatite. Journal of Biomedical Materials Research Part A 99(1):58-66 (2011).
[cited by applicant]
Sai, et al., Quantification of Plasma Cell-free DNA in Patients with Gastric Cancer. Anticancer Research 27(4C):2747-2752 (2007).
[cited by applicant]
Sakakura, et al., Quantitative Analysis of Tumor-derived Methylated RUNX3 Sequences in the Serum of Gastric Cancer Patients. Anticancer Research 29:2619-2626 (2009).
[cited by applicant]
Salkeni, et al., Detection of EGFRvIII Mutant DNA in the Peripheral Blood of Brain Tumor Patients. Journal of Neuro-Oncology 115(1):27-35 (2013).
[cited by applicant]
Sawabu, et al., Serum Tumor Markers and Molecular Biological Diagnosis in Pancreatic Cancer. Pancreas 28(3):263-267 (2004).
[cited by applicant]
Schwarzenbach, et al., Detection and Monitoring of Cell-free DNA in Blood of Patients With Colorectal Cancer. Annals of the New York Academy of Sciences 1137:190-196 (2008).
[cited by applicant]
Schwarzenbach, et al., Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression. Clinical Cancer Research 18:5719-5730 (2012).
[cited by applicant]
Sharma, et al., DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumor Biology 33(6):1837-1843 (2012).
[cited by applicant]
Shaw, et al., Genomic Analysis of Circulating Cell-free DNA Infers Breast Cancer Dormancy. GenomeResearch 22(2):220-231 (2012).
[cited by applicant]
Sonnenberg, et al., Dielectrophoretic Isolation and Detection of Cancer-related Circulating Cell-free DNA Biomarkers From Blood and Plasma. Electrophoresis 35(12-13):1828-1836 (2014).
[cited by applicant]
Sonnenberg, et al., Dielectrophoretic Isolation and Detection of Cfc-DNA Nanoparticulate Biomarkers and Virus From Blood. Electrophoresis 34(7):1076-1084 (2013).
[cited by applicant]
Sonnenberg, et al., Dielectrophoretic Isolation of DNA and Nanoparticles from Blood.Electrophoresis 33(16):2482-2490 (2012).
[cited by applicant]
Sorenson, et al., Detection of Mutated KRAS2 Sequences as Tumor Markers in Plasma/Serum of Patients with Gastrointestinal Cancer. Clinical Cancer Research 6:2129-2137 (2000).
[cited by applicant]
Sosnowski, et al., Rapid Determination of Single Base Mismatch Mutations in DNA Hybrids by Direct Electric Field Control. Pnas USA 94:1119-1123 (1997).
[cited by applicant]
Stephens, et al., The dielectrophoresis enrichment of CD34+ cells from peripheral blood stern cell harvests. Bone Marrow Transplant 18:777-782 (1996).
[cited by applicant]
Stroun, et al., Isolation and Characterization of Dna From the Plasma of Cancer Patients. European Journal of Cancer and Clinical Oncology 23:707-712 (1987).
[cited by applicant]
Swaminathan et al. Enhanced sub-micron colloidal particle separation with interdigitated microelectrode arrays using mixed AC/DC dielectrophoretic scheme. Biomedical Microdevices 17(2):1-9 (2015).
[cited by applicant]
Swanson, et al., A fully multiplexed CMOS biochip for DNA analysis. Sensors and Actuators B 64:22-30 (2000).
[cited by applicant]
Tamkovich, et al., Cell-surface-bound Circulating DNA as a Prognostic Factor in Lung Cancer. Annals of the New York Academy of Sciences 1137:214-217 (2008).
[cited by applicant]
Tanaka, et al., Role of Circulating Free Alu DNA in Endometrial Cancer. International Journal of Gynecological Cancer 22(1):82-86 (2012).
[cited by applicant]
Tangkijvanich, et al., Serum Line-1 Hypomethylation as a Potential Prognostic Marker for Hepatocellular Carcinoma. Clinica Chimica Acta 379(1-2):127-133 (2007).
[cited by applicant]
Tani, et al., An Early Detection of Recurrence Using Reverse Transcriptase-polymerase Chain Reaction (RT-PCP) and Methylation-specific Polymerase Chain Reaction (MSP) From Peripheral Blood in Patients After Gastrectomy.…
[cited by applicant]
Tomita, et al., Quantification of Circulating Plasma DNA Fragments as Tumor Markers in Patients with Esophageal Cancer. Anticancer Research 27(4C):2737-2742 (2007).
[cited by applicant]
Toner, et al., Blood-on-a-chip. Annual Review of Biomedical Engineering 7:77-103 (2005).
[cited by applicant]
Tong, et al., Diagnostic Developments Involving Cell-free (Circulating) Nucleic Acids. Clinica Chimica Acta 363:187-96 (2006).
[cited by applicant]
Toth, et al., Free Circulating Dna Based Colorectal Cancer Screening From Peripheral Blood: the Possibility of the Methylated Septin 9 Gene Marker. Orvosi Hetilap 150(21):969-977(2009) (English Abstract).
[cited by applicant]
Trevisiol, et al., Prognostic Value of Circulating Kras2 Gene Mutations in Colorectal Cancer With Distant Metastases. The International Journal of Biological Markers 21(4):223-228 (2006).
[cited by applicant]
Turner, et al., Cancer Detection at your Fingertips: Smartphone-Enabled DNA Testing. Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2018:5418-5421 (2018).
[cited by applicant]
Tuukanen, et al., Carbon Nanotubes as Electrodes for Dielectrophoresis of DNA. Nano Letters 6:1339-1343 (2006).
[cited by applicant]
Umetani, et al., Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU Repeats. Clinical Chemistry 52(6):1062-1069 (2006).
[cited by applicant]
Umetani, et al., Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum. Journal of Clinical Oncology 24(26):4270-4276 (2006).
[cited by applicant]
Wallner et al., Methylation of Serum DNA Is an Independent Prognostic Marker in Colorectal Cancer. Clinical Cancer Research 12(24):7347-7352 (2006).
[cited by applicant]
Ward et al., Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from
[cited by applicant]
Washizu et al., Applications of Electrostatic Stretch-and-positioning Of DNA. Industry Applications. IEEE Transactions on Industry Applications 31:447-456 (1995).
[cited by applicant]
Washizu et al., Electrostatic Manipulation of DNA in Microfabricated Structures. Industry Applications. IEEE Transactions on Industry Applications 26:1165-1172 (1990).
[cited by applicant]
Weaver et al., Methylated Tumor-specific Dna as a Plasma Biomarker in Patients With Glioma. Cancer Invest 24(1):35-40 (2006).
[cited by applicant]
Weiss et al., Circulating Tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine 369(1):93 (2013).
[cited by applicant]
Widschwendter et al., CDH1 and CDH13 Methylation in Serum is an Independent Prognostic Marker in Cervical Cancer Patients. International Journal of Cancer 109(2):163-166 (2004).
[cited by applicant]
Wu et al., Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clinica Chimica Acta 321(1-2):77-87 (2002).
[cited by applicant]
Xie et al., Quantification of plasma DNA as a screening tool for lung cancer. Chinese Medical Journal 117(10):1485-1488 (2004).
[cited by applicant]
Xue et al., Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clinica Chimica Acta 404(2):100-4 (2009).
[cited by applicant]
Yoon et al., Comparison of Circulating Plasma DNA Levels between Lung Cancer Patients and Healthy Controls. Journal of Molecular Diagnostics 11(3):182-185 (2009).
[cited by applicant]
Zachariah et al., Circulating cell-free DNA as a Potential Biomarker for Minimal and Mild Endometriosis. Reprod Biomed Online 18(3):407-411 (2009).
[cited by applicant]
Zachariah et al., Levels of Circulating Cell-free Nuclear and Mitochondrial DNA in Benign and Malignant Ovarian Tumors. Obstetrics & Gynecology 112(4):843-850 (2008).
[cited by applicant]
Zhang et al. Individually addressable microelectrode arrays fabricated with gold-coated pencil graphite particles for multiplexed and high sensitive impedance immunoassays. Biosensors And Bioelectronics 25(1):34-40 (200…
[cited by applicant]
Zhou et al., Circulating Cell-free Nucleic Acids: Promising Biomarkers of Hepatocellular Carcinoma. Seminars in Oncology 39(4):440-448 (2012).
[cited by applicant]
Ziegler et al., Circulating DNA: A New Diagnostic Gold Mine? Cancer Treatment Reviews 28:255-271 (2002).
[cited by applicant]
Zurita et al., Hypermethylated 14-3-3-σ and ESR1 Gene Promoters in Serum as Candidate Biomarkers for the Diagnosis and Treatment Efficacy of Breast Cancer Metastasis. BMC Cancer 10(217)9 (2010).
[cited by applicant]
AU Serial No. 2018392601 Office Action dated Jun. 12, 2024.
[cited by applicant]
CN Serial No. 2021800547774 Office Action dated May 22, 2025.
[cited by applicant]
CN Serial No. 2023101301490 Office Action dated May 27, 2025.
[cited by applicant]